ERBB2 and breast carcinoma: While these NK-92/5.28.z cells efficiently lysed HER2-expressing tumor cells in vitro, their specific recognition and cytotoxicity of HER2-positive tumor cells were obtained in vivo, resulting in selective enrichment of NK-92/5.28.z cells in orthotopic breast carcinoma xenografts, and reduction of pulmonary metastasis in a renal cell carcinoma model, respectively [135].